TongliBio announcs to receive a clearance letter from the US FDA for its IND application of TL-010
Time:2018-10-15

10/15/2018. TongliBio announcs to receive a clearance letter from the US FDA for its IND application of TL-010 in treatment of schistosomiasis advanced to clinical Phase I trial.